F2G Logo

The Rare Antifungal Disease Company

Overview

F2G is a world-leading UK- and Austria-based Biotech company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. Our goal is to bring to market novel antifungal agents which are differentiated from the existing agents in terms of mechanism of action. Globally, there is an unmet medical need for therapies that are active against resistant infections and also against pathogens which have been difficult to treat historically.

About Us

F2G is a world-leading UK- and Austria-based Biotech company (F2G Ltd and F2G Biotech GmbH) focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides target dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This is a completely different mechanism from that of the currently marketed antifungal agents and gives the orotomides fungicidal activity against a broad range of rare and resistant fungal mould infections. Olorofim (formerly F901318) is F2G’s leading candidate from this class and is in a Phase 2b open-label study focussing on rare and resistant invasive fungal infections such as aspergillosis (including azole-resistant strains), scedosporiosis, and lomentosporiosis. Olorofim is being developed both as IV and oral formulations.

Antifungal Market

The world market for antifungal agents is currently worth in excess of US$6 billion with consistent annual growth driven by year-on-year increases in the susceptible immune compromised patient population. Increases in cancer, organ transplants and use of potent drugs, including broad spectrum antibiotics has led to significant increases in fungal infections. Fungi are now recognised as a major issue in several respiratory conditions, being responsible for exacerbations of symptoms in asthma, COPD and bronchiectasis patients. This is likely to increase the use of antifungal drugs over the coming years.

There are only three major drug classes; triazoles, polyenes and echinocandins plus flucytosine. The polyenes have been available for over 50 years and the introduction of amphotericin B in the 1960’s radically changed the survival hopes of patients with serious fungal infections. The azoles brought the possibility of oral treatment and have shown better tolerability overall than the polyenes. The echinocandins are the latest class of agent to be introduced to the market, but there has not been a new class of agents for over 15 years.

Crude mortality remains high amongst haemato-oncology and intensive care patients and increasing resistance is being seen amongst Candida and Aspergillus species. The mechanisms for this may be partly due to overuse of antifungals, but with Aspergillus species two main mechanisms have been identified; one is chronic use in respiratory patients where it is almost impossible to clear the infection, and the second is acquisition of strains which have developed resistance due to the use of azoles in agriculture. Other rare moulds such as the Zygomycetes, Scedosporium and Lomentosporum species are also becoming more prevalent, are challenging to differentiate from aspergillosis and can be difficult to treat.

Other pathogens such as Coccidioides species are endemic to particular parts of the world and can be contracted by otherwise healthy individuals, causing chronic debilitating disease. Olorofim has activity in vitro and in animal models, against a wide range of endemic mycoses, including Coccidioides species and may offer an alternative to the currently-available agents.

F2G believes that its novel agent, olorofim, and subsequent agents, will address some of the many challenges which face the treating physician and the patient with invasive fungal infections.

Careers

F2G is staffed by highly motivated scientists and physicians. When recruiting we look for candidates with a science background, integrity and excellent interpersonal and organisational skills. We embrace diversity.

Since our culture is one of expected achievement driven by our passion for what we do, we are looking for individuals who thrive on working in a team-oriented environment but are also self-motivated and can work independently. It is through individual talents that we make F2G successful.

Pipeline

2017 2018 2019 2020 2021 2022 2023
Olorofim IV & PO Aspergillus and difficult moulds
Phase 1
Phase 2
Phase 3
 
               
Olorofim IV & PO Specific rare moulds    
Phase 2
Phase 3
               
Broad-spectrum Program
Pre-clinical
Clinical
 

Compassionate access to treatment

F2G is aware that there are limited treatment options available for some patients with rare and difficult-to-treat mould infections. While we recognize the medical need, we must also work within the confines of a drug development system and the limitations that imposes. Our lead compound, olorofim, is currently in an early stage of clinical development and as such its safety and effectiveness are still being evaluated. read more

Investors

F2G is supported by a blue-chip investor syndicate which includes:

For information on investing in F2G please contact

email: contact@f2g.com or telephone: +44 (0)161 785 1270

Contact Us

To find out more about F2G or to give us your feedback, please contact us via:

UK Telephone

+44 (0)161 785 1270

fax

+44 (0)161 785 1273

Austria Telephone

+43 (0)1 997 4267

UK Email

contact@f2g.com

F2G Ltd, Lankro Way, Eccles, Manchester, M30 0LX, United Kingdom

Registered in England and Wales. Company Registration No. 03578625, VAT Reg No. 712680645.


Austria Telephone

+43 (0)1 997 4267

Austria Email

office-AT@f2g.com

F2G Biotech GmbH, Goethegasse 3/2/2, 1010 Vienna, Austria


Medical Information Enquiries

Telephone

+44 (0)161 785 1270